Existing research indicates that in HCC patients receiving nilotinib treatment for 12 months, high expression of ABCC4 and ABCC5 pumps out the drug, downregulating ABCD3, and inducing upregulation of chromosomal replication, cell proliferation, DNA replication, and DNA damage checkpoints (59). Here, ABCD3 is linked to hepatocellular carcinoma.